They're also just doing analysis on a static data set. > PED was determined by manual review of medical narratives for all subjects with ED. Risk of an adverse effect was expressed as number needed to harm (NNH). So…
0.8% of a 4000+ sample size had PED with the regular dosage for baldness treatment. That's absurdly low and pretty much confirms that though the risk is there, it's highly unlikely. Its even more ridiculous that 1.4% of…
I'm a fin user and frankly I'm surprised to see this here. It's already well known that persistent ED is a potential side. I'm guessing its here because its a new study and other HN readers are curious about the drug…
> Among men 16–42 years old and exposed to finasteride ≤1.25 mg/day, 34 of 4,284 (0.8%) developed PED (persistence median 1,534 days, IQR 651–2,351 days); the multivariable model predicting PED had one variable:…
They're also just doing analysis on a static data set. > PED was determined by manual review of medical narratives for all subjects with ED. Risk of an adverse effect was expressed as number needed to harm (NNH). So…
0.8% of a 4000+ sample size had PED with the regular dosage for baldness treatment. That's absurdly low and pretty much confirms that though the risk is there, it's highly unlikely. Its even more ridiculous that 1.4% of…
I'm a fin user and frankly I'm surprised to see this here. It's already well known that persistent ED is a potential side. I'm guessing its here because its a new study and other HN readers are curious about the drug…
> Among men 16–42 years old and exposed to finasteride ≤1.25 mg/day, 34 of 4,284 (0.8%) developed PED (persistence median 1,534 days, IQR 651–2,351 days); the multivariable model predicting PED had one variable:…